Core Insights - Nexalin Technology, Inc. has received Institutional Review Board (IRB) approval for a clinical trial at the University of California, San Diego (UCSD) to evaluate its HALO™ Clarity devices for treating mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) in military and civilian populations [1][2] Company Overview - Nexalin Technology specializes in developing innovative neurostimulation products aimed at addressing the global mental health crisis, utilizing non-invasive bioelectronic medical technology [4] - The company's proprietary Deep Intracranial Frequency Stimulation (DIFS™) technology offers a drug-free alternative for neurological and mental health conditions, minimizing side effects associated with traditional treatments [6] Clinical Trial Details - The initial shipment of HALO™ Clarity devices has been delivered to UCSD, with patient recruitment for the study commencing immediately [1][3] - An additional 40-50 HALO devices will be supplied as the study progresses, which will be integrated with Nexalin's app-controlled remote monitoring system for real-time tracking of patient progress [3][6] Technology and Advantages - The HALO™ Clarity device is designed for non-invasive deep-brain stimulation, providing a patient-centered treatment experience [3] - The combination of DIFS technology with an advanced virtual clinic model allows for seamless oversight of treatment adherence and progress [3][6] Future Aspirations - The initiation of patient recruitment is viewed as a significant milestone in validating the HALO Clarity device for TBI and PTSD treatment, with the potential to make non-invasive deep brain stimulation a viable solution for affected individuals [3]

HOUSTON, TX, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that following Institutional Review Board (IRB) approval, the University of California, San Diego (UCSD) has received the first shipment of HALO™ Clarity devices to commence its  clinical trial evaluating the treatment of mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) ...

Core Insights - Nexalin Technology, Inc. has appointed General Wesley K. Clark (Ret.) to its Military & Government Advisory Board to enhance its neurostimulation solutions for the U.S. military and government sectors [1][3][4] - The company's "Nexalin America" initiative focuses on addressing mental health issues such as post-traumatic stress disorder (PTSD), traumatic brain injury, and substance use disorder [1][3] Company Overview - Nexalin Technology specializes in developing non-invasive neurostimulation products aimed at combating the global mental health crisis [5] - The company's devices utilize bioelectronic medical technology to target deep brain structures associated with mental health disorders, promising enhanced patient responses without adverse side effects [5] Advisory Board Contributions - General Clark's extensive military experience and leadership will support Nexalin's integration of its deep-brain stimulation devices into military healthcare initiatives [2][3] - The Military & Government Advisory Board aims to foster relationships with federal agencies, including the U.S. Department of Defense and the Department of Veterans Affairs [4]

HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is honored to announce that General Wesley K. Clark (Ret.), former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. General Clark will collaborate with esteemed members David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy, and William A. Hudson, Jr., ...

HOUSTON, TX, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces that it has received Institutional Review Board (IRB) approval from the University of California, San Diego (UCSD) for clinical testing of its HALO™ Clarity (HALO) headset in human subjects. This study is being conducted independently by UCSD. Nexalin is providing the HALO devices for research purposes ...

HOUSTON, TEXAS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces its appointment as Industry Co-Chair of the National Traumatic Brain Injury (TBI) Registry Coalition. This appointment emphasizes Nexalin's commitment to advancing TBI advocacy and research, particularly in collaboration with policymakers and stakeholders in Washington, D.C. "We are honored to be na ...

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces the publication of a landmark study in the Journal of Affective Disorders demonstrating the potential efficacy of its proprietary DIFS technology. The research highlights the potential of DIFS to deliver meaningful reductions in systolic and diastolic blood pressure in patients with major depressive dis ...

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, announces the publication of a landmark study in the Journal of Affective Disorders demonstrating the potential efficacy of its proprietary DIFS technology. The research highlights the potential of DIFS to deliver meaningful reductions in systolic and diastolic blood pressure in patients with major depressive dis ...

HOUSTON, TX, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) is pleased to invite investors to a webinar today, January 23, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Nexalin CEO Mark White, who will share insight into the Company’s growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Ne ...

DIFS Technology: A Potential Game-Changer for Mental Health Treatments Setting New Benchmarks: 65% Response Rate Shown in Completed Depression Trials Alzheimer’s Research Shows Promising Results with Increased Brain Activity Virtual Clinic Poised to Revolutionize Mental Health Care with AI Integration Pursuing CE Mark to Expand into European Markets in 2025 Strategic Focus on PTSD, TBI, and Addiction Research for Veterans Global Growth with Approvals in China, Brazil, and Oman Neuromodulation Market Positi ...